{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T05:56:50Z","timestamp":1781416610306,"version":"3.54.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32AI007384-28"],"award-info":[{"award-number":["5T32AI007384-28"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Encephalopathy complicates beta-lactam therapy, particularly with impaired renal function, though no studies have reported ceftaroline-associated encephalopathy. Among 28 patients with estimated glomerular filtration rates &amp;lt;30 mL\/min who received \u22655 days of ceftaroline, 3 developed encephalopathy. Ceftaroline, when dosed supra-therapeutically for serious infections, may be a cause of antibiotic-associated encephalopathy.<\/jats:p>","DOI":"10.1093\/cid\/ciz857","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T18:45:20Z","timestamp":1567017920000},"page":"2002-2004","source":"Crossref","is-referenced-by-count":9,"title":["Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment"],"prefix":"10.1093","volume":"70","author":[{"given":"Thomas C S","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Chow","sequence":"first","affiliation":[{"name":"Veterans Affairs San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T","family":"Johns","sequence":"first","affiliation":[{"name":"Veterans Affairs San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R","family":"Mehta","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California"},{"name":"Veterans Affairs San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2020041501060144600_CIT0001","volume-title":"Ceftraroline product label","author":"Food and Drug Administration","year":"2010"},{"key":"2020041501060144600_CIT0002","doi-asserted-by":"crossref","first-page":"ofx084","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020041501060144600_CIT0003","doi-asserted-by":"crossref","first-page":"963\u201371","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya","year":"2016","journal-title":"Neurology"},{"key":"2020041501060144600_CIT0004","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40264-017-0578-2","article-title":"Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review","volume":"40","author":"Deshayes","year":"2017","journal-title":"Drug Saf"},{"key":"2020041501060144600_CIT0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz857\/30121968\/ciz857.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/9\/2002\/33045609\/ciz857.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/9\/2002\/33045609\/ciz857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T05:07:00Z","timestamp":1586927220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/9\/2002\/5556474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":5,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,8,29]]},"published-print":{"date-parts":[[2020,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz857","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5,1]]},"published":{"date-parts":[[2019,8,29]]}}}